Within-subjects (MDMA)

PreclinicalSmall molecule

Within-subjects (MDMA) is one of 3 small molecule programs targeting Emotional Processing. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Emotional ProcessingCompleted

Emotional ProcessingPreclinical

Completed

Competition

Competitive Landscape

3 competitors in Emotional Processing

#DrugCompanyPhaseTrials

D-Cycloserine

MMassachusetts General Hospital

Preclinical

1 2

Within-subjects (MDMA)

UUniversity of Chicago

Preclinical

1 3

Vasoconstrictor (otrivin)

UUniversity of Electronic Science and Technology of China

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Emotional Processing1 trial

Effects of MDMA on Social and Emotional Processing

Completed·UUniversity of Chicago·N/A·NCT01849419·65 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Within-subjects (MDMA). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Within-subjects (MDMA) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Within-subjects (MDMA). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Chicago company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Chicago

Within-subjects (MDMA)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Emotional Processing1 trial

References

Drug Info

Quick Facts

Related News